Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia.

Trial Profile

Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2018

At a glance

  • Drugs Cariprazine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 20 Nov 2018 Results of post hoc analyses using pooled data from the 3 Phase II/III trials (NCT00694707, NCT01104766, NCT01104779); published in the European Neuropsychopharmacology
    • 09 Nov 2017 Results of pooled data from 6 trial (RGH-MD-31, RGH-MD-32, RGH-MD-33, RGH-MD-04, RGH-MD-05 and RGH-MD-16) assessing global improvement with cariprazine in the treatment of biploar I disorder and schizophrenia, were published in the International Journal of Clinical Practice.
    • 20 Sep 2016 Post hoc pooled analysis results of this (NCT00694707) and other trials (NCT01058096, NCT00488618, NCT00404573, NCT01104766, NCT01058668, NCT01104779) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top